[Corrigendum] WEE1 inhibition by MK1775 as a single‑agent therapy inhibits ovarian cancer viability
- Authors:
- Published online on: May 21, 2018 https://doi.org/10.3892/ol.2018.8757
- Pages: 1366-1366
-
Copyright : © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Article
Oncol Lett 14: [Related article:] 3580-3586, 2017; DOI: 10.3892/ol.2017.6584
Following the publication of this article, an interested reader drew to our attention an error in the published text: On p. 3580, the first sentence of the Abstract should have read as “Wee1-like protein kinase (WEE1) physiologically serves a key function in maintaining the integrity of the cell genome through mediating the inactivation of cyclin-dependent kinase (CDK)1 and CDK2.” (i.e., “activation” was featured incorrectly).
Likewise, the first sentence in the Introduction should have read as “Wee1-like protein kinase (WEE1) … contributes to the upstream regulation of the cyclin-dependent kinase (CDK) complexes by mediating the inactivation of CDK1.”
We apologize that these errors were allowed to remain in the paper, and regret the inconvenience that this has caused.